261 related articles for article (PubMed ID: 26389833)
21. Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients.
Ma L; Hao S; Diong C; Goh YT; Gopalakrishnan S; Ho A; Hwang W; Koh LP; Koh M; Lim ZY; Loh Y; Poon M; Tan LK; Tan P; Linn YC
Leuk Lymphoma; 2015 May; 56(5):1362-9. PubMed ID: 25139689
[TBL] [Abstract][Full Text] [Related]
22. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?
Nishiwaki S; Atsuta Y; Tanaka J
Bone Marrow Transplant; 2013 Nov; 48(11):1369-76. PubMed ID: 23474804
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Nakasone H
Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
[TBL] [Abstract][Full Text] [Related]
25. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
26. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
[TBL] [Abstract][Full Text] [Related]
28. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?
Litzow MR
Best Pract Res Clin Haematol; 2016 Dec; 29(4):345-350. PubMed ID: 27890258
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
[TBL] [Abstract][Full Text] [Related]
30. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
31. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
Litzow MR
Best Pract Res Clin Haematol; 2018 Dec; 31(4):357-360. PubMed ID: 30466747
[TBL] [Abstract][Full Text] [Related]
33. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Nishiwaki S; Miyamura K; Ohashi K; Kurokawa M; Taniguchi S; Fukuda T; Ikegame K; Takahashi S; Mori T; Imai K; Iida H; Hidaka M; Sakamaki H; Morishima Y; Kato K; Suzuki R; Tanaka J;
Ann Oncol; 2013 Jun; 24(6):1594-602. PubMed ID: 23372050
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
35. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
[TBL] [Abstract][Full Text] [Related]
37. Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival.
Nakasone H; Kako S; Tachibana T; Tanaka M; Onizuka M; Takahashi S; Yokota A; Fujiwara SI; Sakura T; Sakaida E; Fujisawa S; Yamazaki R; Gotoh M; Hagihara M; Aotsuka N; Tsukada N; Hatta Y; Shimizu H; Usuki K; Watanabe R; Mori T; Yano S; Kanamori H; Kanda Y
Transplant Cell Ther; 2021 Sep; 27(9):800.e1-800.e8. PubMed ID: 34171522
[TBL] [Abstract][Full Text] [Related]
38. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Onizuka M
Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.
Saadeh SS; Litzow MR
Expert Rev Hematol; 2018 Mar; 11(3):195-207. PubMed ID: 29376437
[TBL] [Abstract][Full Text] [Related]
40. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
